search button
Open Access

Real‑world data indicated that neoadjuvant chemotherapy alone was associated with a higher risk of tumor recurrence in high‑risk breast cancer subgroup patients

  • Authors:
    • Zhensheng Li
    • Yue Li
    • Yunjiang Liu
    • Yuguang Shang
    • Yarong Zhou
    • Xiaohui Ji
    • Huina Han
    • Kaiye Du
    • Jun Zhang

  • View Affiliations

  • Published online on: March 30, 2023     https://doi.org/10.3892/ol.2023.13779
  • Article Number: 193

  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Numerous clinical trials have reported equal effects of tumor control between neoadjuvant chemotherapy (NAC) and adjuvant chemotherapy (AC) in patients with breast cancer (BC). However, this conclusion has not been verified in practice. The present retrospective study evaluated if there were different risk profiles for NAC, AC and their combinative modes on disease‑free survival (DFS) in patients with BC using real‑world data. All women with primary unilateral Stage I‑III BC and first recurrence in 2008‑2018 at The Fourth Hospital of Hebei Medical University were retrospectively identified for enrollment. The four modes of chemotherapy administered for primary BC were classified as ‘None’, ‘NAC only’, ‘NAC+AC’ and ‘AC only’. One multivariate Cox model was used to estimate the adjusted Hazard Ratio (HR) and P‑value. Covariates included age, Easter Cooperative Oncology Group grade, T stage, N stage, pathology, grade, lymphovascular invasion (LVI), BC subtype, number of chemotherapy cycles and other therapies. Amongst 637 patients, who had a mean age of 48.2 years at BC diagnosis and 50.9 years at recurrence, the median DFS by the ‘None’ (n=27), ‘NAC only’ (n=47), ‘NAC+AC’ (n=118) and ‘AC only’ (n=445) modes were 31.4, 16.6, 22.6 and 28.4 months (P<0.001), respectively. Compared with the ‘AC only’, adjusted HR (P‑value) of the ‘None’, ‘NAC only’ and ‘NAC+AC’ modes on tumor recurrence were 1.182 (0.551), 1.481 (0.037) and 1.102 (0.523), respectively. The adjusted HR of ‘NAC only’ vs. ‘AC only’ modes were 1.448 (P=0.157) for locoregional recurrence and 2.675 (P=0.003) for distant recurrence. Stratified analyses further indicated that the ‘NAC only’ mode was associated with a higher recurrence risk in T3‑4, N2‑3, LVI‑positive, or HER2‑negative subgroup patients. In conclusion, NAC alone was associated with a higher risk of tumor recurrence in high‑risk BC subgroup patients in real‑world data. Patient selection of chemotherapy mode was involved in practice but could not fully explain this finding. The ‘inadequate’ NAC was highly likely to have accounted for this observation.
View Figures
View References

Related Articles

Journal Cover

May-2023
Volume 25 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.9
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 6.3
  • CiteScore Rank: Q2: #119/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.725
  • SCImago Journal Rank (SJR): 0.639
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Li Z, Li Y, Liu Y, Shang Y, Zhou Y, Ji X, Han H, Du K and Zhang J: Real‑world data indicated that neoadjuvant chemotherapy alone was associated with a higher risk of tumor recurrence in high‑risk breast cancer subgroup patients. Oncol Lett 25: 193, 2023
APA
Li, Z., Li, Y., Liu, Y., Shang, Y., Zhou, Y., Ji, X. ... Zhang, J. (2023). Real‑world data indicated that neoadjuvant chemotherapy alone was associated with a higher risk of tumor recurrence in high‑risk breast cancer subgroup patients. Oncology Letters, 25, 193. https://doi.org/10.3892/ol.2023.13779
MLA
Li, Z., Li, Y., Liu, Y., Shang, Y., Zhou, Y., Ji, X., Han, H., Du, K., Zhang, J."Real‑world data indicated that neoadjuvant chemotherapy alone was associated with a higher risk of tumor recurrence in high‑risk breast cancer subgroup patients". Oncology Letters 25.5 (2023): 193.
Chicago
Li, Z., Li, Y., Liu, Y., Shang, Y., Zhou, Y., Ji, X., Han, H., Du, K., Zhang, J."Real‑world data indicated that neoadjuvant chemotherapy alone was associated with a higher risk of tumor recurrence in high‑risk breast cancer subgroup patients". Oncology Letters 25, no. 5 (2023): 193. https://doi.org/10.3892/ol.2023.13779